Symbols / APYX Stock $3.83 -1.79% Apyx Medical Corporation
APYX (Stock) Chart
About
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Surgical Aesthetics and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures; and a portfolio of single-use handpieces and accessories for open and laparoscopic procedures. The company's helium plasma technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures OEM generators and related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
Stock Fundamentals
Scroll to Statements| Market Cap | 160.21M | Enterprise Value | 168.10M | Income | -11.21M | Sales | 52.84M | Book/sh | 0.35 | Cash/sh | 0.76 |
| Dividend Yield | — | Payout | 0.00% | Employees | 205 | IPO | — | P/E | — | Forward P/E | -13.58 |
| PEG | 0.59 | P/S | 3.03 | P/B | 11.01 | P/C | — | EV/EBITDA | -29.03 | EV/Sales | 3.18 |
| Quick Ratio | 4.16 | Current Ratio | 5.00 | Debt/Eq | 265.25 | LT Debt/Eq | — | EPS (ttm) | -0.27 | EPS next Y | -0.28 |
| EPS Growth | — | Revenue Growth | 34.70% | Earnings | 2026-05-07 | ROA | -6.12% | ROE | -76.15% | ROIC | — |
| Gross Margin | 62.53% | Oper. Margin | 0.06% | Profit Margin | -21.22% | Shs Outstand | 41.83M | Shs Float | 29.09M | Short Float | 0.49% |
| Short Ratio | 1.35 | Short Interest | — | 52W High | 4.50 | 52W Low | 0.82 | Beta | 1.54 | Avg Volume | 129.06K |
| Volume | 99.96K | Target Price | $6.40 | Recom | Strong_buy | Prev Close | $3.90 | Price | $3.83 | Change | -1.79% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-11 | main | Craig-Hallum | Buy → Buy | $6 |
| 2026-03-11 | up | BTIG | Neutral → Buy | $6 |
| 2025-12-16 | init | Roth Capital | — → Buy | $6 |
| 2025-11-12 | up | Citizens | Market Perform → Market Outperform | $8 |
| 2024-10-17 | init | BTIG | — → Neutral | — |
| 2024-09-16 | reit | JMP Securities | — → Market Perform | — |
| 2023-11-10 | main | Stephens & Co. | Overweight → Overweight | $5 |
| 2023-08-11 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2023-07-14 | init | Stephens & Co. | — → Overweight | $8 |
| 2023-06-15 | main | Lake Street | — → Buy | $9 |
| 2023-05-24 | reit | JMP Securities | — → Market Perform | — |
| 2023-05-12 | main | Lake Street | Buy → Buy | $6 |
| 2022-08-12 | main | Piper Sandler | — → Overweight | $12 |
| 2022-07-19 | main | Lake Street | — → Buy | $17 |
| 2022-05-20 | init | Lake Street | — → Buy | $12 |
| 2021-08-13 | main | JMP Securities | — → Market Outperform | $14 |
| 2020-05-12 | main | JMP Securities | — → Market Outperform | $5 |
| 2019-11-12 | main | Piper Sandler | — → Overweight | $10 |
| 2019-04-02 | main | JMP Securities | Market Outperform → Market Outperform | $8 |
- APYX Apyx Medical Corporation posts narrower Q4 2025 loss than analyst estimates, shares climb modestly. - Revenue Per Share - Xã Thanh Hà hu, 23 Apr 2026 08
- APYX | Apyx Medical Corporation Common Insider Trading - Quiver Quantitative Fri, 17 Apr 2026 12
- How The Apyx Medical (APYX) Narrative Is Shifting With New Targets Guidance And Growth Drivers - Yahoo Finance ue, 21 Apr 2026 16
- APYX Apyx Medical Corporation posts narrower Q4 2025 loss than analyst estimates, shares climb modestly. - Profit Announcement - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 21
- APYX Earnings History & Surprises | EPS & Revenue Results | APYX MEDICAL CORP (NASDAQ:APYX) - ChartMill Fri, 17 Apr 2026 07
- Subdued Growth No Barrier To Apyx Medical Corporation (NASDAQ:APYX) With Shares Advancing 26% - simplywall.st ue, 03 Feb 2026 08
- Renuvion wins NewBeauty again, extending its skin-tightening streak - Stock Titan Wed, 01 Apr 2026 07
- Why is Apyx Medical (APYX) Stock moving today | Price at $3.87, Down 3.37% - Top Trending Breakouts - Cổng thông tin điện tử Tỉnh Sơn La Fri, 10 Apr 2026 07
- Earnings call transcript: Apyx Medical Q4 2025 revenue beats forecast, stock rises - Investing.com ue, 10 Mar 2026 07
- Apyx Medical Stock Strengthens On AYON Launch And U.S. Aesthetics Demand - RTTNews ue, 13 Jan 2026 08
- Is Agenus (AGEN) Outperforming Other Medical Stocks This Year? - Yahoo Finance Mon, 20 Apr 2026 13
- Apyx Medical Corporation Announces Commencement of Underwritten Public Offering of Common Stock - Quiver Quantitative Mon, 17 Nov 2025 08
- Apyx Medical (APYX) SVP exercises stock options to acquire 37,000 shares - Stock Titan ue, 17 Mar 2026 07
- How The Apyx Medical (APYX) Story Is Evolving With New Growth Drivers And Profitability Goals - Yahoo Finance Mon, 23 Mar 2026 07
- APYX MEDICAL ($APYX) Releases Q4 2025 Earnings - Quiver Quantitative ue, 10 Mar 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
52.84
+9.86%
|
48.10
-8.11%
|
52.35
+17.61%
|
44.51
|
| Operating Revenue |
|
52.84
+9.86%
|
48.10
-8.11%
|
52.35
+17.61%
|
44.51
|
| Cost Of Revenue |
|
19.80
+5.65%
|
18.74
+0.82%
|
18.59
+20.88%
|
15.38
|
| Reconciled Cost Of Revenue |
|
19.80
+5.65%
|
18.74
+0.82%
|
18.59
+20.88%
|
15.38
|
| Gross Profit |
|
33.04
+12.55%
|
29.36
-13.03%
|
33.76
+15.89%
|
29.13
|
| Operating Expense |
|
39.49
-18.08%
|
48.20
-10.25%
|
53.71
+1.93%
|
52.69
|
| Research And Development |
|
3.37
-33.60%
|
5.08
-6.62%
|
5.44
+19.72%
|
4.54
|
| Selling General And Administration |
|
36.12
-16.25%
|
43.12
-10.66%
|
48.27
+0.25%
|
48.15
|
| General And Administrative Expense |
|
36.12
-16.25%
|
43.12
-10.66%
|
48.27
+0.25%
|
48.15
|
| Salaries And Wages |
|
14.01
-19.26%
|
17.35
-8.87%
|
19.04
+2.26%
|
18.62
|
| Other Gand A |
|
22.11
-14.22%
|
25.77
-11.83%
|
29.23
-1.01%
|
29.53
|
| Total Expenses |
|
59.29
-11.44%
|
66.95
-7.40%
|
72.30
+6.21%
|
68.07
|
| Operating Income |
|
-6.45
+65.79%
|
-18.84
+5.54%
|
-19.95
+15.33%
|
-23.56
|
| Total Operating Income As Reported |
|
-6.45
+65.79%
|
-18.84
-9.19%
|
-17.26
+26.75%
|
-23.56
|
| EBITDA |
|
-4.59
+72.67%
|
-16.80
+7.24%
|
-18.11
+17.70%
|
-22.01
|
| Normalized EBITDA |
|
-4.59
+72.67%
|
-16.80
+5.16%
|
-17.72
+19.49%
|
-22.01
|
| Reconciled Depreciation |
|
0.66
+9.35%
|
0.60
-13.44%
|
0.69
-22.25%
|
0.89
|
| EBIT |
|
-5.25
+69.85%
|
-17.40
+7.47%
|
-18.80
+17.87%
|
-22.90
|
| Total Unusual Items |
|
—
|
0.00
+100.00%
|
-0.40
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
0.00
+100.00%
|
-0.40
|
0.00
|
| Special Income Charges |
|
—
|
0.00
+100.00%
|
-0.40
|
0.00
|
| Other Special Charges |
|
—
|
—
|
0.40
|
—
|
| Net Income |
|
-11.21
+52.22%
|
-23.46
-25.38%
|
-18.71
+19.28%
|
-23.18
|
| Pretax Income |
|
-10.84
+53.51%
|
-23.31
-9.52%
|
-21.28
+7.11%
|
-22.91
|
| Net Non Operating Interest Income Expense |
|
-4.48
-4.19%
|
-4.30
-176.24%
|
-1.56
-1196.48%
|
0.14
|
| Interest Expense Non Operating |
|
5.59
-5.38%
|
5.91
+138.38%
|
2.48
+16420.00%
|
0.01
|
| Net Interest Income |
|
-4.48
-4.19%
|
-4.30
-176.24%
|
-1.56
-1196.48%
|
0.14
|
| Interest Expense |
|
5.59
-5.38%
|
5.91
+138.38%
|
2.48
+16420.00%
|
0.01
|
| Interest Income Non Operating |
|
1.11
-31.01%
|
1.61
+74.38%
|
0.92
+486.62%
|
0.16
|
| Interest Income |
|
1.11
-31.01%
|
1.61
+74.38%
|
0.92
+486.62%
|
0.16
|
| Other Income Expense |
|
0.09
+157.14%
|
-0.16
-171.24%
|
0.23
-55.60%
|
0.51
|
| Other Non Operating Income Expenses |
|
0.09
+157.14%
|
-0.16
-125.88%
|
0.62
+22.20%
|
0.51
|
| Tax Provision |
|
0.27
+7.14%
|
0.25
+110.36%
|
-2.43
-762.67%
|
0.37
|
| Tax Rate For Calcs |
|
0.00
+0.00%
|
0.00
+84.21%
|
0.00
-45.71%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
+100.00%
|
-0.05
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-11.11
+52.86%
|
-23.56
-24.98%
|
-18.85
+19.02%
|
-23.28
|
| Net Income From Continuing Operation Net Minority Interest |
|
-11.21
+52.22%
|
-23.46
-25.38%
|
-18.71
+19.28%
|
-23.18
|
| Net Income From Continuing And Discontinued Operation |
|
-11.21
+52.22%
|
-23.46
-25.38%
|
-18.71
+19.28%
|
-23.18
|
| Net Income Continuous Operations |
|
-11.11
+52.86%
|
-23.56
-24.98%
|
-18.85
+19.02%
|
-23.28
|
| Minority Interests |
|
-0.11
-210.42%
|
0.10
-29.93%
|
0.14
+45.74%
|
0.09
|
| Normalized Income |
|
-11.21
+52.22%
|
-23.46
-27.78%
|
-18.36
+20.80%
|
-23.18
|
| Net Income Common Stockholders |
|
-11.21
+52.22%
|
-23.46
-25.38%
|
-18.71
+19.28%
|
-23.18
|
| Diluted EPS |
|
-0.27
+59.09%
|
-0.66
-22.22%
|
-0.54
+19.40%
|
-0.67
|
| Basic EPS |
|
-0.27
+59.09%
|
-0.66
-22.22%
|
-0.54
+19.40%
|
-0.67
|
| Basic Average Shares |
|
41.09
+15.62%
|
35.54
+2.66%
|
34.62
+0.31%
|
34.52
|
| Diluted Average Shares |
|
41.09
+15.62%
|
35.54
+2.66%
|
34.62
+0.31%
|
34.52
|
| Diluted NI Availto Com Stockholders |
|
-11.21
+52.22%
|
-23.46
-25.38%
|
-18.71
+19.28%
|
-23.18
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
66.84
+3.08%
|
64.84
-18.17%
|
79.24
+53.05%
|
51.77
|
| Current Assets |
|
58.47
+3.60%
|
56.44
-19.79%
|
70.36
+63.74%
|
42.97
|
| Cash Cash Equivalents And Short Term Investments |
|
31.74
0.00%
|
31.74
-27.29%
|
43.65
+328.30%
|
10.19
|
| Cash And Cash Equivalents |
|
31.74
0.00%
|
31.74
-27.29%
|
43.65
+328.30%
|
10.19
|
| Receivables |
|
16.78
+8.37%
|
15.48
+10.39%
|
14.02
-23.14%
|
18.25
|
| Accounts Receivable |
|
16.78
+8.37%
|
15.48
+10.39%
|
14.02
+32.27%
|
10.60
|
| Allowance For Doubtful Accounts Receivable |
|
-1.02
-2.00%
|
-1.00
-64.47%
|
-0.61
+8.98%
|
-0.67
|
| Other Receivables |
|
—
|
—
|
0.03
-69.70%
|
0.10
|
| Taxes Receivable |
|
—
|
—
|
0.00
-100.00%
|
7.54
|
| Inventory |
|
8.60
+13.72%
|
7.56
-23.77%
|
9.92
-15.89%
|
11.80
|
| Raw Materials |
|
4.88
+22.95%
|
3.97
-3.38%
|
4.11
-17.41%
|
4.98
|
| Work In Process |
|
2.19
+14.44%
|
1.92
-15.02%
|
2.26
+4.49%
|
2.16
|
| Finished Goods |
|
2.73
+0.89%
|
2.71
-38.93%
|
4.43
-13.41%
|
5.12
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
1.35
-18.25%
|
1.66
-40.12%
|
2.76
+0.99%
|
2.74
|
| Total Non Current Assets |
|
8.37
-0.39%
|
8.40
-5.36%
|
8.88
+0.85%
|
8.80
|
| Net PPE |
|
6.62
-1.80%
|
6.74
-5.71%
|
7.15
-5.80%
|
7.59
|
| Gross PPE |
|
10.91
+1.71%
|
10.73
+0.55%
|
10.67
-15.51%
|
12.63
|
| Accumulated Depreciation |
|
-4.29
-7.62%
|
-3.99
-13.26%
|
-3.52
+30.13%
|
-5.04
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Land And Improvements |
|
—
|
—
|
0.00
-100.00%
|
1.60
|
| Buildings And Improvements |
|
—
|
—
|
0.00
-100.00%
|
4.43
|
| Machinery Furniture Equipment |
|
4.99
+21.82%
|
4.10
+5.02%
|
3.90
-8.06%
|
4.24
|
| Construction In Progress |
|
0.16
-74.49%
|
0.64
+58.75%
|
0.40
-21.10%
|
0.51
|
| Other Properties |
|
5.39
-5.57%
|
5.71
-7.17%
|
6.15
+268.06%
|
1.67
|
| Leases |
|
0.36
+28.47%
|
0.28
+32.55%
|
0.21
+19.10%
|
0.18
|
| Other Non Current Assets |
|
1.75
+5.29%
|
1.66
-3.93%
|
1.73
+42.32%
|
1.22
|
| Total Liabilities Net Minority Interest |
|
52.01
+2.97%
|
50.51
-3.46%
|
52.32
+274.18%
|
13.98
|
| Current Liabilities |
|
11.70
+9.13%
|
10.72
-15.85%
|
12.74
+7.51%
|
11.85
|
| Payables And Accrued Expenses |
|
8.88
-8.20%
|
9.67
-6.45%
|
10.34
-3.76%
|
10.74
|
| Payables |
|
3.06
+16.94%
|
2.62
-3.58%
|
2.71
-42.88%
|
4.75
|
| Accounts Payable |
|
3.06
+16.94%
|
2.62
-3.58%
|
2.71
+1.61%
|
2.67
|
| Current Accrued Expenses |
|
5.82
-17.51%
|
7.06
-7.47%
|
7.63
+27.22%
|
6.00
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.75
|
0.00
-100.00%
|
1.54
|
0.00
|
| Total Tax Payable |
|
—
|
—
|
0.00
-100.00%
|
2.08
|
| Current Debt And Capital Lease Obligation |
|
0.43
+20.56%
|
0.35
-3.27%
|
0.37
+45.06%
|
0.25
|
| Current Capital Lease Obligation |
|
0.43
+20.56%
|
0.35
-3.27%
|
0.37
+45.06%
|
0.25
|
| Current Deferred Liabilities |
|
0.64
-7.22%
|
0.69
+42.01%
|
0.49
-42.79%
|
0.85
|
| Current Deferred Revenue |
|
0.64
-7.22%
|
0.69
+42.01%
|
0.49
-42.79%
|
0.85
|
| Other Current Liabilities |
|
—
|
—
|
—
|
2.08
|
| Total Non Current Liabilities Net Minority Interest |
|
40.31
+1.31%
|
39.79
+0.53%
|
39.58
+1756.38%
|
2.13
|
| Long Term Debt And Capital Lease Obligation |
|
38.91
+1.31%
|
38.41
+0.72%
|
38.13
+6922.84%
|
0.54
|
| Long Term Debt |
|
34.85
+2.82%
|
33.89
+2.13%
|
33.19
|
—
|
| Long Term Capital Lease Obligation |
|
4.06
-10.03%
|
4.52
-8.75%
|
4.95
+811.42%
|
0.54
|
| Non Current Deferred Liabilities |
|
1.05
-6.08%
|
1.12
-10.27%
|
1.25
-11.51%
|
1.41
|
| Non Current Deferred Revenue |
|
1.05
-6.08%
|
1.12
-10.27%
|
1.25
-11.51%
|
1.41
|
| Other Non Current Liabilities |
|
0.35
+33.98%
|
0.26
+30.81%
|
0.20
+9.39%
|
0.18
|
| Stockholders Equity |
|
14.54
+2.32%
|
14.21
-46.78%
|
26.70
-28.95%
|
37.58
|
| Capital Stock |
|
0.04
+10.53%
|
0.04
+8.57%
|
0.04
+0.00%
|
0.04
|
| Common Stock |
|
0.04
+10.53%
|
0.04
+8.57%
|
0.04
+0.00%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
41.79
+10.56%
|
37.79
+9.09%
|
34.64
+0.13%
|
34.60
|
| Ordinary Shares Number |
|
41.79
+10.56%
|
37.79
+9.09%
|
34.64
+0.13%
|
34.60
|
| Additional Paid In Capital |
|
103.62
+12.53%
|
92.08
+13.52%
|
81.11
+10.69%
|
73.28
|
| Retained Earnings |
|
-89.12
-14.39%
|
-77.91
-43.09%
|
-54.45
-52.37%
|
-35.73
|
| Minority Interest |
|
0.29
+132.80%
|
0.12
-43.44%
|
0.22
+4.74%
|
0.21
|
| Total Equity Gross Minority Interest |
|
14.83
+3.46%
|
14.34
-46.75%
|
26.92
-28.76%
|
37.79
|
| Total Capitalization |
|
49.39
+2.67%
|
48.10
-19.68%
|
59.89
+59.35%
|
37.58
|
| Working Capital |
|
46.77
+2.30%
|
45.72
-20.66%
|
57.62
+85.15%
|
31.12
|
| Invested Capital |
|
49.39
+2.67%
|
48.10
-19.68%
|
59.89
+59.35%
|
37.58
|
| Total Debt |
|
39.34
+1.49%
|
38.76
+0.68%
|
38.50
+4736.81%
|
0.80
|
| Net Debt |
|
3.11
+44.47%
|
2.15
|
—
|
—
|
| Capital Lease Obligations |
|
4.49
-7.80%
|
4.87
-8.37%
|
5.32
+567.84%
|
0.80
|
| Net Tangible Assets |
|
14.54
+2.32%
|
14.21
-46.78%
|
26.70
-28.95%
|
37.58
|
| Tangible Book Value |
|
14.54
+2.32%
|
14.21
-46.78%
|
26.70
-28.95%
|
37.58
|
| Inventories Adjustments Allowances |
|
-1.21
-16.96%
|
-1.03
-17.94%
|
-0.88
-91.47%
|
-0.46
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-8.00
+55.67%
|
-18.05
-243.82%
|
-5.25
+74.12%
|
-20.28
|
| Cash Flow From Continuing Operating Activities |
|
-8.00
+55.67%
|
-18.05
-243.82%
|
-5.25
+74.12%
|
-20.28
|
| Net Income From Continuing Operations |
|
-11.11
+52.86%
|
-23.56
-24.98%
|
-18.85
+19.02%
|
-23.28
|
| Depreciation Amortization Depletion |
|
0.66
+9.35%
|
0.60
-13.44%
|
0.69
-22.25%
|
0.89
|
| Depreciation And Amortization |
|
0.66
+9.35%
|
0.60
-13.44%
|
0.69
-22.25%
|
0.89
|
| Other Non Cash Items |
|
1.04
-17.89%
|
1.27
+100.79%
|
0.63
|
—
|
| Stock Based Compensation |
|
2.00
-50.14%
|
4.01
-21.53%
|
5.11
-23.64%
|
6.70
|
| Provisionand Write Offof Assets |
|
0.98
+13.33%
|
0.86
-18.81%
|
1.06
+92.22%
|
0.55
|
| Operating Gains Losses |
|
0.02
+46.15%
|
0.01
-97.67%
|
0.56
+642.67%
|
0.07
|
| Gain Loss On Sale Of PPE |
|
0.02
+46.15%
|
0.01
+100.51%
|
-2.53
-3474.67%
|
0.07
|
| Change In Working Capital |
|
-1.59
-27.79%
|
-1.25
-122.46%
|
5.54
+206.25%
|
-5.22
|
| Change In Receivables |
|
-1.32
+35.23%
|
-2.04
-151.25%
|
3.97
+97.07%
|
2.02
|
| Changes In Account Receivables |
|
-1.32
+35.23%
|
-2.04
+43.06%
|
-3.57
-286.34%
|
1.92
|
| Change In Inventory |
|
-1.07
-147.46%
|
2.26
+55.11%
|
1.46
+126.20%
|
-5.57
|
| Change In Prepaid Assets |
|
0.24
-72.35%
|
0.86
+555.85%
|
-0.19
+64.05%
|
-0.52
|
| Change In Payables And Accrued Expense |
|
0.56
+124.21%
|
-2.33
-874.09%
|
0.30
+126.38%
|
-1.14
|
| Change In Accrued Expense |
|
0.21
+109.22%
|
-2.27
-921.38%
|
0.28
+122.85%
|
-1.21
|
| Change In Payable |
|
0.35
+663.49%
|
-0.06
-352.00%
|
0.03
-62.69%
|
0.07
|
| Change In Account Payable |
|
0.35
+663.49%
|
-0.06
-352.00%
|
0.03
-62.69%
|
0.07
|
| Investing Cash Flow |
|
-1.11
-54.29%
|
-0.72
-110.72%
|
6.73
+766.73%
|
-1.01
|
| Cash Flow From Continuing Investing Activities |
|
-1.11
-54.29%
|
-0.72
-110.72%
|
6.73
+766.73%
|
-1.01
|
| Net PPE Purchase And Sale |
|
-1.11
-54.29%
|
-0.72
-110.72%
|
6.73
+766.73%
|
-1.01
|
| Purchase Of PPE |
|
-1.11
-54.29%
|
-0.72
-35.46%
|
-0.53
+47.23%
|
-1.01
|
| Sale Of PPE |
|
—
|
0.00
-100.00%
|
7.27
|
0.00
|
| Capital Expenditure |
|
-1.11
-54.29%
|
-0.72
-35.46%
|
-0.53
+47.23%
|
-1.01
|
| Financing Cash Flow |
|
9.58
+42.03%
|
6.75
-79.03%
|
32.17
+14723.04%
|
0.22
|
| Cash Flow From Continuing Financing Activities |
|
9.58
+42.03%
|
6.75
-79.03%
|
32.17
+14723.04%
|
0.22
|
| Net Issuance Payments Of Debt |
|
-0.02
+0.00%
|
-0.02
-100.06%
|
35.04
+23775.00%
|
-0.15
|
| Issuance Of Debt |
|
—
|
0.00
-100.00%
|
46.11
|
0.00
|
| Repayment Of Debt |
|
-0.02
+0.00%
|
-0.02
+99.82%
|
-11.07
-7377.70%
|
-0.15
|
| Long Term Debt Issuance |
|
—
|
0.00
-100.00%
|
46.11
|
0.00
|
| Long Term Debt Payments |
|
-0.02
+0.00%
|
-0.02
+99.82%
|
-11.07
-7377.70%
|
-0.15
|
| Net Long Term Debt Issuance |
|
-0.02
+0.00%
|
-0.02
-100.06%
|
35.04
+23775.00%
|
-0.15
|
| Net Common Stock Issuance |
|
9.30
+32.86%
|
7.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
0.49
|
0.00
-100.00%
|
0.09
-76.44%
|
0.36
|
| Net Other Financing Charges |
|
-0.19
+20.00%
|
-0.23
+92.06%
|
-2.96
|
—
|
| Effect Of Exchange Rate Changes |
|
-0.47
-512.39%
|
0.11
+159.16%
|
-0.19
-148.35%
|
0.40
|
| Beginning Cash Position |
|
31.74
-27.29%
|
43.65
+328.30%
|
10.19
-66.98%
|
30.87
|
| End Cash Position |
|
31.74
0.00%
|
31.74
-27.29%
|
43.65
+328.30%
|
10.19
|
| Free Cash Flow |
|
-9.12
+51.44%
|
-18.77
-224.61%
|
-5.78
+72.84%
|
-21.29
|
| Interest Paid Supplemental Data |
|
4.64
-2.32%
|
4.75
+145.27%
|
1.94
+12800.00%
|
0.01
|
| Income Tax Paid Supplemental Data |
|
0.26
-32.46%
|
0.38
+16.11%
|
0.33
+157.03%
|
0.13
|
| Common Stock Issuance |
|
9.30
+32.86%
|
7.00
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
9.30
+32.86%
|
7.00
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-03-17 View
- 10-K2026-03-10 View
- 8-K2026-03-10 View
- 42026-01-29 View
- 8-K2026-01-12 View
- 8-K2025-12-12 View
- 8-K2025-11-19 View
- 10-Q2025-11-06 View
- 8-K2025-11-06 View
- 8-K2025-08-13 View
- 10-Q2025-08-07 View
- 8-K2025-08-07 View
- 42025-05-19 View
- 42025-05-19 View
- 42025-05-19 View
- 42025-05-19 View
- 42025-05-19 View
- 42025-05-19 View
- 42025-05-19 View
- 8-K2025-05-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|